CORRESP Filing
CNS Pharmaceuticals, Inc.
Date: April 17, 2025 · CIK: 0001729427 · Accession: 0001683168-25-002655
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-286529
Letter
CNS Pharmaceuticals, Inc.
2100 West Loop South, Suite 900
Houston, TX 77027
April 17, 2025
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporate Finance
Washington, DC 20549
Attention: Alan Campbell
Re: CNS Pharmaceuticals, Inc.
Registration Statement on Form S-1
Registration No. 333-286529
Ladies and Gentlemen:
Reference is made to our letter, filed as correspondence with the U.S. Securities and Exchange Commission via EDGAR on April 14, 2025, in which we requested the acceleration of the effective date of the above-captioned Registration Statement on April 16, 2025, at 5:00 P.M. (Eastern Time). We are no longer requesting that the Registration Statement be declared effective at that date and time, and we hereby formally withdraw our prior request for acceleration of the effective date of the above-captioned Registration Statement, as amended.
Very truly yours,
CNS Pharmaceuticals, Inc.
Show Raw Text
CORRESP 1 filename1.htm CNS Pharmaceuticals, Inc. 2100 West Loop South, Suite 900 Houston, TX 77027 April 17, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporate Finance Washington, DC 20549 Attention: Alan Campbell Re: CNS Pharmaceuticals, Inc. Registration Statement on Form S-1 Registration No. 333-286529 Ladies and Gentlemen: Reference is made to our letter, filed as correspondence with the U.S. Securities and Exchange Commission via EDGAR on April 14, 2025, in which we requested the acceleration of the effective date of the above-captioned Registration Statement on April 16, 2025, at 5:00 P.M. (Eastern Time). We are no longer requesting that the Registration Statement be declared effective at that date and time, and we hereby formally withdraw our prior request for acceleration of the effective date of the above-captioned Registration Statement, as amended. Very truly yours, CNS Pharmaceuticals, Inc. By: /s/ Christopher Downs Name: Christopher Downs Title: Chief Financial Officer